

**WI-IL Agility Group**  
**CPE Trial Profit & Loss**  
**All Transactions**

	<u>19-03MarCPE</u>	<u>19-05MayCPE</u>	<u>19-06JunCPE</u>	<u>19-07JulCPE</u>	<u>19-09SepCPE</u>	<u>19-12DecCPE</u>	<u>20-03MarCPE</u>	<u>20-07JulCPE</u>
<b>Ordinary Income/Expense</b>								
<b>Income</b>								
<b>303 · Trial Income</b>								
<b>303.3 · CPE Trials</b>	8,810.50	9,331.00	5,245.00	10,584.00	7,178.00	8,613.00	7,167.25	4,116.00
<b>Total 303 · Trial Income</b>	8,810.50	9,331.00	5,245.00	10,584.00	7,178.00	8,613.00	7,167.25	4,116.00
<b>Total Income</b>	8,810.50	9,331.00	5,245.00	10,584.00	7,178.00	8,613.00	7,167.25	4,116.00
<b>Cost of Goods Sold</b>								
<b>403 · Trial Expenses</b>								
<b>403.2 · AKC Trials</b>	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>403.3 · CPE Trials</b>	3,954.61	3,945.69	3,563.80	4,548.61	3,478.95	4,123.77	3,093.33	1,550.44
<b>Total 403 · Trial Expenses</b>	3,954.61	3,945.69	3,563.80	4,548.61	3,478.95	4,123.77	3,093.33	1,550.44
<b>408 · Judges Fees</b>								
<b>408.3 · Judges Fees - CPE</b>	772.00	737.00	0.00	869.00	564.00	725.00	624.00	398.00
<b>Total 408 · Judges Fees</b>	772.00	737.00	0.00	869.00	564.00	725.00	624.00	398.00
<b>Total COGS</b>	4,726.61	4,682.69	3,563.80	5,417.61	4,042.95	4,848.77	3,717.33	1,948.44
<b>Gross Profit</b>	4,083.89	4,648.31	1,681.20	5,166.39	3,135.05	3,764.23	3,449.92	2,167.56
<b>Net Ordinary Income</b>	4,083.89	4,648.31	1,681.20	5,166.39	3,135.05	3,764.23	3,449.92	2,167.56
<b>Net Income</b>	<b>4,083.89</b>	<b>4,648.31</b>	<b>1,681.20</b>	<b>5,166.39</b>	<b>3,135.05</b>	<b>3,764.23</b>	<b>3,449.92</b>	<b>2,167.56</b>

**WI-IL Agility Group**  
**CPE Trial Profit & Loss**  
All Transactions

	<u>20-09SepCPE</u>	<u>21-03MarCPE</u>	<u>21-05MayCPE</u>	<u>21-06JunCPE</u>	<u>21-07JulCPE</u>	<u>21-09SepCPE</u>	<u>TOTAL</u>
<b>Ordinary Income/Expense</b>							
<b>Income</b>							
<b>303 · Trial Income</b>							
<b>303.3 · CPE Trials</b>	4,995.00	6,169.00	5,999.00	4,490.00	5,615.00	5,184.00	93,496.75
<b>Total 303 · Trial Income</b>	4,995.00	6,169.00	5,999.00	4,490.00	5,615.00	5,184.00	93,496.75
<b>Total Income</b>	4,995.00	6,169.00	5,999.00	4,490.00	5,615.00	5,184.00	93,496.75
<b>Cost of Goods Sold</b>							
<b>403 · Trial Expenses</b>							
<b>403.2 · AKC Trials</b>	0.00	0.00	0.00	0.00	0.00	25.00	25.00
<b>403.3 · CPE Trials</b>	1,660.66	3,074.73	2,779.43	2,253.33	1,948.70	2,668.58	42,644.63
<b>Total 403 · Trial Expenses</b>	1,660.66	3,074.73	2,779.43	2,253.33	1,948.70	2,693.58	42,669.63
<b>408 · Judges Fees</b>							
<b>408.3 · Judges Fees - CPE</b>	475.00	571.00	529.00	400.00	428.00	588.75	7,680.75
<b>Total 408 · Judges Fees</b>	475.00	571.00	529.00	400.00	428.00	588.75	7,680.75
<b>Total COGS</b>	2,135.66	3,645.73	3,308.43	2,653.33	2,376.70	3,282.33	50,350.38
<b>Gross Profit</b>	2,859.34	2,523.27	2,690.57	1,836.67	3,238.30	1,901.67	43,146.37
<b>Net Ordinary Income</b>	2,859.34	2,523.27	2,690.57	1,836.67	3,238.30	1,901.67	43,146.37
<b>Net Income</b>	<b>2,859.34</b>	<b>2,523.27</b>	<b>2,690.57</b>	<b>1,836.67</b>	<b>3,238.30</b>	<b>1,901.67</b>	<b>43,146.37</b>